🇺🇸 Campath-1H in United States

17 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Deep Vein Thrombosis — 2 reports (11.76%)
  2. Epstein-Barr Virus Infection — 2 reports (11.76%)
  3. Gastroenteritis Adenovirus — 2 reports (11.76%)
  4. Graft Versus Host Disease — 2 reports (11.76%)
  5. Post Procedural Complication — 2 reports (11.76%)
  6. Pyrexia — 2 reports (11.76%)
  7. Thrombophlebitis Superficial — 2 reports (11.76%)
  8. Adenoviral Hepatitis — 1 report (5.88%)
  9. Adenovirus Infection — 1 report (5.88%)
  10. Angioimmunoblastic T-Cell Lymphoma — 1 report (5.88%)

Source database →

Campath-1H in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Campath-1H approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Campath-1H in United States?

Baylor College of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.